Helsingborg-based HealthTech startup Xaga Surgical has raised € 700,000 (SEK 8 million) in an investment round to expand its operations to the U.S. and further develop its innovative medical needles aimed at reducing infection risks and improving cancer diagnostics. The round included about € 250,000 from Almi and similar amount from SmiLe Inject Capital, alongside private investors.
Addressing Critical Challenges in Healthcare
Xaga Surgical, founded in 2016 by urologist Dr. Andreas Forsvall, focuses on transforming needle technology to address significant risks associated with bacterial infections during biopsies. Dr. Forsvall was inspired by two patients who developed sepsis after prostate biopsies, revealing the limitations of conventional needle designs.
Xaga Surgical is tackling a significant issue in healthcare: reducing bacterial infections and improving cancer diagnostics through innovative needle design. The company’s technology has been developed to address the risks associated with traditional needle usage, which expose over 50 million people annually to health issues related to needle infections.
“The global market for medical needles faces significant challenges. Over 50 million people annually risk health problems linked to needle infections, with estimated costs of $80 billion USD. Our technology is designed to address this need and create safer and more efficient healthcare solutions,”
says Andreas Forsvall, founder and CEO of Xaga Surgical.
Expanding Swedish Innovation on a Global Scale
The funding will be used to commercialize Xaga Surgical’s patented needle technology, which reduces bacterial transmission by 96%, and to facilitate entry into international markets. The company aims to secure FDA approval and position itself as a leader in infection prevention and cancer diagnostics.
“Our investment in Xaga Surgical is an example of how we support innovations that make a real difference. Through their groundbreaking technology, we can contribute to safer healthcare and strengthen Sweden’s competitiveness in a global market,”
says Faten Mustafa, Investment Manager at Almi Invest.
With a focus on addressing the estimated 3.4 million hospital-acquired infections caused by needles annually, Xaga Surgical’s innovative approach positions the company as a key player in transforming patient safety and outcomes. The new funding marks a significant milestone in Xaga Surgical’s mission to enhance global healthcare solutions.